AMLX
Income statement / Annual
Last year (2023), Amylyx Pharmaceuticals, Inc.'s total revenue was $380.79 M,
an increase of 1,612.94% from the previous year.
In 2023, Amylyx Pharmaceuticals, Inc.'s net income was $49.27 M.
See Amylyx Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$380.79 M
|
$22.23 M
|
$285,000.00
|
$650,000.00
|
$1.43 M
|
| Cost of Revenue |
$25.44 M |
$2.99 M |
$52,000.00 |
$24.59 M |
$11.90 M |
| Gross Profit |
$355.35 M |
$19.24 M |
$233,000.00 |
-$23.94 M |
-$10.47 M |
| Gross Profit Ratio |
0.93 |
0.87 |
0.82 |
-36.84 |
-7.34 |
| Research and Development
Expenses |
$128.19 M
|
$93.45 M
|
$44.04 M
|
$24.59 M
|
$11.90 M
|
| General & Administrative
Expenses |
$178.86 M
|
$127.13 M
|
$38.93 M
|
$15.06 M
|
$3.08 M
|
| Selling & Marketing
Expenses |
$9.50 M
|
$4.40 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$188.36 M
|
$127.13 M
|
$38.93 M
|
$15.06 M
|
$3.08 M
|
| Other Expenses |
$0.00 |
$3.74 M |
-$285,000.00 |
-$650,000.00 |
-$1.43 M |
| Operating Expenses |
$316.54 M |
$220.58 M |
$82.69 M |
$39.01 M |
$13.55 M |
| Cost And Expenses |
$341.98 M |
$223.57 M |
$82.69 M |
$39.01 M |
$13.55 M |
| Interest Income |
$16.16 M |
$4.29 M |
$36,000.00 |
$14,000.00 |
$176,000.00 |
| Interest Expense |
$0.00 |
$4.29 M |
$0.00 |
$2.29 M |
$1.28 M |
| Depreciation &
Amortization |
$1.09 M
|
$487,000.00
|
$52,000.00
|
$1,000.00
|
$13.55 M
|
| EBITDA |
$39.89 M
|
-$200.85 M
|
-$82.64 M
|
-$39.00 M
|
$1.11 M
|
| EBITDA Ratio |
0.1 |
-9.06 |
-290.13 |
-59.57 |
-9.38 |
| Operating Income Ratio
|
0.1
|
-9.06
|
-290.13
|
-60.01
|
-9.5
|
| Total Other
Income/Expenses Net |
$15.50 M
|
$3.74 M
|
-$5.24 M
|
-$3.28 M
|
-$162,000.00
|
| Income Before Tax |
$54.30 M |
-$197.60 M |
-$87.93 M |
-$42.28 M |
-$13.72 M |
| Income Before Tax Ratio
|
0.14
|
-8.89
|
-308.53
|
-65.05
|
-9.62
|
| Income Tax Expense |
$5.03 M |
$774,000.00 |
-$52,000.00 |
$2.56 M |
$1.10 M |
| Net Income |
$49.27 M |
-$198.38 M |
-$87.88 M |
-$44.84 M |
-$14.82 M |
| Net Income Ratio |
0.13 |
-8.92 |
-308.35 |
-68.98 |
-10.39 |
| EPS |
0.73 |
-2.98 |
-1.52 |
-0.79 |
-0.26 |
| EPS Diluted |
0.7 |
-2.98 |
-1.52 |
-0.79 |
-0.26 |
| Weighted Average Shares
Out |
$67.23 M
|
$66.51 M
|
$57.86 M
|
$56.47 M
|
$56.47 M
|
| Weighted Average Shares
Out Diluted |
$69.99 M
|
$66.51 M
|
$57.86 M
|
$56.47 M
|
$56.47 M
|
| Link |
|
|
|
|
|
